Undiluted I.V.-Hepabig inj not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “undiluted I.V.-Hepabig inj(GC5103) 10,000 International Unit”In the company’s words, NCT05686759 on ClinicalTrials.gov
- Tested for
- Hepatitis B
- Main trialPhase 3
- “The purpose of this study is to evaluate the efficacy and safety of undiluted intravenous infusion of I.V.-Hepabig inj. in post-liver transplant patients”In the company’s words, NCT05686759 on ClinicalTrials.gov
Other drugs for Hepatitis B
- GST-HG141Fujian Akeylink Biotechnology Co., Ltd. · Phase 3
- AHB-137Ausper Biopharma Co., Ltd. · Phase 3
- In-House Recombinant Hepatitis B vaccinePT Bio Farma · Phase 3
- ZM-H1505RShanghai Zhimeng Biopharma, Inc. · Phase 3
- LBVDLG Chem · Phase 2/3
- TQA3605Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Jun 2026 | A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026